Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 404-407

  Lafeuillade, Alain ^a   Poggi, Cécile ^b   Profizi, Nérina ^b   Tamalet, Catherine ^b   Costes, Olivier ^b  

^a Hopital Chalucet Toulon   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CASE REPORT; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIREMIA; VIRUS TITRATION;

EID: 0030010777     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.404     Document Type: Article

References (14)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 1995;373:117-22.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-I infection. Nature 1995;373:123-6.
3. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
4. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
5. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
6. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995;377: 740-4.
7. Cohen OJ, Pantaleo G, Holodniy M, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995;82:6017-21.
8. Lafeuillade A, Tamalet C, Tourres C, et al. Lymphoid organs remain important sanctuaries of infections with HIV-1 during zidovudine-ddl combination therapy [abstract 298]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: Infectious Diseases Society of America, 1996.
9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-I dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
10. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [abstract LB7]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: Infectious Diseases Society of America, 1996.
11. Massari F, Conant M, Mellors J, et al. A phase II open label randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract 200]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: Infectious Diseases Society of America, 1996.
12. St. Clair MH, Pennington KM, Rooney J, Barry DW. In vitro comparison of selected triple drug combinations for suppression of HIV-1 replication: the Inter-company Collaboration Protocol. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl 2):S83-91.
13. Manouilov KK, White CA, Boudinot FD, Fedorov II, Chu CK. Lymphatic distribution of 3′-azido-3′-deoxythymidine and 3′-azido-2′,3′-dideoxyuridine in mice. Drug Metab Dispos 1995;23:655-8.
14. Tae-Wook C, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano R. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Med 1995;1:1284-90.